The FDA added six additional drugs to its Commissioner’s National Priority Voucher (CNPV) pilot, expanding a program designed to accelerate review timelines for therapies deemed in the national interest. The second cohort includes high‑profile obesity candidates tied to recent administration efforts to lower drug prices and speed access. Under the pilot, winners can receive accelerated regulatory review—shortening the typical 10–12 month review window to a matter of months—if they qualify and use the voucher. The agency framed the program as an experiment to align expedited reviews with broader policy goals on domestic manufacturing and affordability. The move immediately reshapes near‑term regulatory calculus for companies with late‑stage obesity and other priority drug programs, and will influence commercial and launch planning. It also raises questions across industry about selection criteria, potential market distortions, and how expedited review incentives will be balanced with evidentiary standards.